GYRE Comptes : Analyse IA Gyre Therapeutics Inc

Accueil

Stock

GYRE

GYRE Financier

Gyre Therapeutics Inc

$8.02

2.55%

$0.19

À la fermeture : Feb 13, 16:00:00 GMT-5

$8.02

Post-Marché: Feb 13, 20:00:00 GMT-5

Aperçu Prévision Gagner Dividendes Comptes financiers

Revenus

État de situation

Flux de trésorerie

Annuel

Trimestriellement

GYRE Revenu

Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenus	107	105	113	0	7	20
Croissance des revenus (H/H)	-44%	-7%	--	-100%	-65%	--
Coût des ventes	4	3	4	0	7	9
Bénéfice brut	102	101	108	0	0	11
Vente, Général et Administration	77	73	75	16	18	16
Recherche et développement	12	12	13	12	68	52
Frais d'exploitation	90	85	89	29	87	68
Autres revenus (charges) non opérationnels	2	5	-10	0	0	0
Bénéfice avant impôts	15	23	-76	-7	-87	-56
Charge d'impôt sur le revenu	3	5	8	0	--	--
Bénéfice net	6	12	-92	-8	-87	-56
Croissance du bénéfice net	-108%	-112.99%	1,050%	-91%	55%	2%
Actions en circulation (diluées)	103.97	102.29	65.83	2.1	2.04	1.28
Variation des actions (H-H)	1%	55%	3,035%	3%	59%	60%
EPS (dilué)	0.06	0.11	-1.41	-3.92	-43.1	-43.93
Croissance du EPS	-109%	-108%	-64%	-91%	-2%	-36%
Flux de trésorerie libre	1	-6	17	-33	-84	-55
Flux de trésorerie libre par action	--	--	--	--	--	--
Marge brute	95.32%	96.19%	95.57%	0%	0%	55%
Marge opérationnelle	10.28%	15.23%	16.81%	0%	-1,242.85%	-280%
Marge bénéficiaire	5.6%	11.42%	-81.41%	0%	-1,242.85%	-280%
Marge du flux de trésorerie libre	0.93%	-5.71%	15.04%	0%	-1,200%	-275%
EBITDA	13	17	20	-29	-87	-56
Marge EBITDA	12.14%	16.19%	17.69%	0%	-1,242.85%	-280%
D&A pour le résultat opérationnel	2	1	1	0	0	0
EBIT	11	16	19	-29	-87	-56
Marge EBIT	10.28%	15.23%	16.81%	0%	-1,242.85%	-280%
Taux d'imposition effectif	20%	21.73%	-10.52%	0%	--	--

Statistiques clés

Clôture préc.

$7.82

Prix d'ouverture

Plage de la journée

$8 - $8.19

Plage de 52 semaines

$6.11 - $13.75

Volume

63.0K

Volume moyen

77.6K

BPA (TTM)

0.06

Rendement en dividend

Capitalisation boursière

$728.9M

Qu’est-ce que GYRE ?

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.



Fonctionnalités

Copilote IA pour actions et cryptomonnaies

Prédiction des prix

Suivi des collectes de fonds

Thèmes

Comparaison de cryptomonnaies

Ressources